Limited Distribution Drug

A Limited Distribution Drug (LDD) is a prescription drug whose manufacturer restricts dispensing to a defined network of authorized specialty pharmacies. LDD arrangements arise from REMS programs that require pharmacy certification, from manufacturer-driven decisions to control distribution for high-cost or specialty preparations, and from product-launch frameworks that constrain dispensing to data-collecting pharmacies. LDD network removal can effectively end a specialty pharmacy's ability to dispense the affected drug.

How Limited Distribution Drug networks work

The manufacturer or its authorized agent maintains the LDD network and credentials each participating pharmacy on terms set in the network contract. Common LDD contract terms include exclusivity, data reporting obligations (patient outcomes, adherence, REMS-required data), dispensing protocol compliance, periodic recertification, and termination-for-cause provisions tied to compliance findings. The PBM-side relationship runs in parallel: the PBM separately credentials the pharmacy for the underlying claim adjudication, and PBM audit findings can interact with manufacturer-side LDD network status.

When Limited Distribution Drug rules apply

LDD rules apply for the specific drug or drug category covered by the manufacturer's distribution program. A specialty pharmacy may be in the LDD network for one drug and not for another. New drug launches in oncology, rare disease, biologics, and certain specialty categories almost always launch into a defined LDD network. The 2024 to 2026 GLP-1 enforcement context produced LDD-like restrictions on certain compounded GLP-1 preparations, where the manufacturer-equivalent FDA bulks-list restriction substituted for a traditional LDD network.

The dispensing pharmacy's exposure

Network removal eliminates the pharmacy's ability to dispense the affected drug, which for some specialty pharmacies ends a significant revenue line. Recoupment exposure runs through the PBM track on claims dispensed during periods of LDD network noncompliance. Where the manufacturer-side LDD removal is for cause (compliance failure, data falsification, REMS noncompliance), the same conduct often supports parallel FCA exposure where federal payors are involved. The defense framework focuses on the LDD contract compliance record, the REMS documentation, and the manufacturer-relationship management before removal becomes formal.

Related terms

• Specialty pharmacy The pharmacy category whose business model concentrates in LDD networks.
• REMS The FDA program framework that drives many LDD arrangements.
• GLP-1 The drug class whose enforcement context produced LDD-like restrictions on compounded preparations.
• Prior authorization The PBM-side process that often precedes LDD claim dispensing.

See also

• Practice area
  Specialty Pharmacy Audit Defense

  The full specialty pharmacy defense framework including LDD network defense.

• Practice area
  PBM Audit Defense

  PBM audit defense framework where LDD compliance findings surface as PBM audit findings.